SUNNYVALE, California,
January 14, 2016 /PRNewswire/ --
Premier Qatar, Latvian Cancer Centers to Offer
Patients Treatment with the CyberKnife®
System; Leading Bulgarian Hospital to Provide
Treatment with the TomoTherapy®
System
Accuray Incorporated (NASDAQ: ARAY) announced today that the
first centers in Qatar,
Latvia, and Bulgaria are now equipped with its radiation
therapy technology, demonstrating continued momentum in adoption of
its devices in Europe,
India, the Middle East and Africa (EIMEA). The CyberKnife® and
TomoTherapy® Systems are now used in more than 40
countries to treat patients across the full spectrum of radiation
therapy cases, from routine to complex, including brain, breast,
lung, head and neck, pancreas and prostate. With an increasing
number of centers installing the systems, more patients will have
the opportunity to benefit from the extremely precise radiation
treatments they deliver.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://photos.prnewswire.com/prnh/20160108/320402 )
(Photo:
http://photos.prnewswire.com/prnh/20160108/320403 )
For more information on the CyberKnife and TomoTherapy Systems
visit http://www.accuray.com.
Qatar: first CyberKnife
System in the Gulf Cooperation Council
The National Center for Cancer Care and Research, located in
Doha, is the first center in the
region to be equipped with Accuray technology. The installation of
the CyberKnife M6™ Series makes it possible for patients to receive
treatment with one of the most advanced radiation therapy systems
on the market.
Latvia: first CyberKnife
System in the Baltic countries
The stereotactic radiosurgery center (SRC) 'Sigulda,' located in
Sigulda, is the first center to offer CyberKnife M6 System
treatments in the Baltic region. SRC 'Sigulda' plans to use the
system to treat both oncological and non-oncological diseases.
The CyberKnife M6 Series delivers radiosurgery and stereotactic
body radiation therapy (SBRT), enabling precise, high-quality dose
distributions to be confidently administered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. Using its unique
robotic range of motion and continuous image guidance, the system
follows the target throughout the treatment process, delivering
individualized treatment with sub-millimeter precision.
Bulgaria: first TomoTherapy
System in the country
The New Radiotherapy Clinic in SBALO- Specialized Hospital for
Active Treatment in Oncology, located in Sofia, will be the first hospital in
Bulgaria to offer patients
treatment with the TomoTherapy® System. SBALO selected this system
because it is the only radiation system specifically designed for
image-guided intensity-modulated radiation therapy.
Based on a CT scanner platform, the TomoTherapy®
System provides continuous delivery of radiation from 360 degrees
around the patient, or delivery from clinician-specified beam
angles. These unique features, combined with daily 3D image
guidance, enable physicians to deliver highly accurate,
individualized dose distributions which precisely conform to the
shape of the patient's tumor while minimizing dose to normal,
healthy tissue, resulting in fewer side effects for patients.
"The recent installations of Accuray technologies in
Qatar, Latvia and Bulgaria indicate clinicians believe in the
long-term benefits our devices can provide to their patients," says
Lionel Hadjadjeba, corporate senior vice president, president
worldwide commercial operations at Accuray. "We're committed to
working with clinical teams around the world to ensure that with
the CyberKnife® and TomoTherapy Systems, they can
significantly and positively impact the way cancer is managed."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to market adoption of the
company's products, clinical applications, clinical results,
patient outcomes and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed under the heading "Risk Factors" in
the company's report on Form 10-K, filed on August 28, 2015, the company's report on Form
10-Q, filed on November 5, 2015, and
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.